Targeting signalling pathways and the immune microenvironment of cancer stem cells—a clinical update

JA Clara, C Monge, Y Yang, N Takebe - Nature reviews clinical …, 2020 - nature.com
Cancer stem cells (CSCs) have important roles in tumour development, relapse and
metastasis; the intrinsic self-renewal characteristics and tumorigenic properties of these cells …

Antitumour dendritic cell vaccination in a priming and boosting approach

A Harari, M Graciotti, M Bassani-Sternberg… - Nature Reviews Drug …, 2020 - nature.com
Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …

[HTML][HTML] Therapeutic potential of CAR T cell in malignancies: A sco** review

AZ Mehrabadi, R Ranjbar, M Farzanehpour… - Biomedicine & …, 2022 - Elsevier
Although tremendous advancements in cancer therapy over the last several years, cancer
still is a complex illness to cure. Traditional cancer treatments, including chemotherapy …

[HTML][HTML] CAR T cell-based immunotherapy for the treatment of glioblastoma

L Maggs, G Cattaneo, AE Dal… - Frontiers in …, 2021 - frontiersin.org
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumor in adults. Current treatment options typically consist of surgery followed by …

Mesothelin-targeted CARs: driving T cells to solid tumors

A Morello, M Sadelain, PS Adusumilli - Cancer discovery, 2016 - AACR
Chimeric antigen receptors (CAR) are synthetic receptors that target T cells to cell-surface
antigens and augment T-cell function and persistence. Mesothelin is a cell-surface antigen …

[HTML][HTML] CAR-T cell therapy for breast cancer: from basic research to clinical application

YH Yang, JW Liu, C Lu, JF Wei - International journal of biological …, 2022 - ncbi.nlm.nih.gov
Breast cancer rises as the most commonly diagnosed cancer in 2020. Among women,
breast cancer ranks first in both cancer incidence rate and mortality. Treatment resistance …

CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy

MC Burger, C Zhang, PN Harter, A Romanski… - Frontiers in …, 2019 - frontiersin.org
Glioblastoma (GB) is the most common and aggressive primary brain tumor in adults and
currently incurable. Despite multimodal treatment regimens, median survival in unselected …

CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil

F Nasiri, M Kazemi, SMJ Mirarefin… - Frontiers in …, 2022 - frontiersin.org
Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat
subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor …

Tumor buster-where will the CAR-T cell therapy 'missile'go?

C Qu, H Zhang, H Cao, L Tang, H Mo, F Liu, L Zhang… - Molecular Cancer, 2022 - Springer
Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing
technology represents a significant breakthrough in personalized immunotherapy for human …

Emerging CAR-T cell therapy for the treatment of triple-negative breast cancer

S Dees, R Ganesan, S Singh, IS Grewal - Molecular cancer therapeutics, 2020 - AACR
Triple-negative breast cancer (TNBC), a highly aggressive breast cancer subtype that lacks
estrogen receptor, progesterone receptor, and HER2 expression, does not respond to …